ACCELERATING RESEARCH TOWARD A CURE
$3.8 million granted to expand research studies across the U.S.

Gastric Cancer Foundation is raising the public profile of gastric (stomach) cancer and increasing the amount of research funding and support dedicated to eradicating the disease.

The Foundation accelerates progress by funding research initiatives to better understand gastric cancer and develop improved methods of prevention, detection and treatment.

Stanford University Medical School and Stanford Genome Technology Center

University of Texas MD Anderson Cancer Center

Washington University School of Medicine

Harvard Medical School and Dana-Farber Cancer Institute

$3.8 million granted to expand research studies across the U.S.

ACCELERATING RESEARCH TOWARD A CURE

LEADING THE SEARCH FOR A CURE

GASTRIC CANCER REGISTRY

The Foundation established the first comprehensive HIPAA-compliant registry at Stanford University Medical Center to create a bridge between patients and researchers who are seeking greater understanding and more effective methods of prevention, diagnosis and treatment. Tumor, blood and saliva samples undergo whole genome sequencing and sophisticated analyses.

Patients and immediate family members who join the registry are important partners in the search for a cure.

LEARN MORE AND REGISTER

DATA AVAILABLE TO ALL RESEARCHERS

The Genome Explorer web portal – a comprehensive database of clinical and genomic information – makes data available to researchers around the globe free of charge. The Gastric Cancer Registry is on track to become the single largest repository of patient information and genomic data for stomach cancer.

PREVIEW THE NEW GENOME EXPLORER WEB PORTAL

EARLY-STAGE RESEARCH FUNDING

Grants provide early funding for investigations that have the potential to open up new possibilities for patient treatments. This type of foundation funding – seed funding at the initial stage of study — is essential in order to generate preliminary data that can be the basis for subsequently applying for larger public grants.

LEARN MORE ABOUT FOUNDATION FUNDED RESEARCH GRANTS

RESEARCH SCHOLAR AWARDS

The Ben Feinstein Memorial Research Scholar Award in Gastric Cancer provides funding and support to enable outstanding young investigators to focus their work on gastric cancer. The Foundation joined with the American Gastroenterological Association (AGA) Foundation to jointly establish this permanently endowed award which provides three-year research grants of $100,000 per year.

MEET OUR SCHOLARS

FIND CLINICAL TRIALS

Clinical trials study the effectiveness of new medicines and treatments. Participation in a clinical trial can offer an additional treatment option to patients while making an important contribution to the field, helping doctors learn more about gastric cancer and how to prevent or treat it.

It can be overwhelming to understand all the studies that are underway and how they might match with your condition. Help is available.

Our free no-obligation clinical trial matching service helps patients navigate this complex landscape to find and match with appropriate clinical trials in their area. Skilled navigators provide individualized support that prepares patients to discuss clinical study possibilities with their medical care team.

LEARN MORE AND REQUEST ASSISTANCE

Speak with a trained navigator by calling 1-855-731-6032, weekdays 8am–6pm ET

Published Research

Gastric Cancer Foundation-supported research discoveries have been published in acclaimed journals.

Oncogenic Fatty Acid Metabolism Rewires Energy Supply Chain in Gastric Carcinogenesis Yoonkyung Won, Bogun Jang Su-Hyung Lee, et al. GI Cancer May 2024; Volume 166, ISSUE 5, P772-786.e14

Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting Aurel Prosz, Pranshu Sahgal, Brandon M. Huffman, et al. NPJ Precis Oncol. 2024; 8: 87

The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric Cancer Hanlee P. Ji et al. Cancer Epidemiol Biomarkers 2022; 31:1693–700

Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. Ryul Kim, Minae An. Hyuk Lee et al. Cancer Discov (2022) 12 (4): 984–1001.

Are You a TMBeliever? Mutations and Atezolizumab Response in Solid Tumors. Steven B. Maron, Samuel J. Klempner. Cancer Discov (2022) 12 (3): 602–603.

Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer. Minsuk Kwon, Minae An, Samuel J. Klempner et al. Cancer Discov (2021) 11 (9): 2168–2185.

Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Wang, J., Xiu, J., Baca, Y. et al. Oncogene 40 2021; 4894–4905.

YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Ajani JA, Xu Y, Huo L, et al. Gut 2021; 70:55-66.

Aim2-mediated/IFN-β–independent regulation of gastric metaplastic lesions via CD8+ T cells. Mohamad El-Zaatari, …, Marilia Cascalho, John Y. Kao. JCI Insight 2020; 5(5):e94035.

Proliferation and Differentiation of Gastric Mucous Neck and Chief Cells During Homeostasis and Injury-induced Metaplasia Joseph Burclaff, Spencer G. Willet,1 José B. Sáenz, et al. Gastroenterology 2020 Feb;158(3):598-609.e5.

Helicobacter pylori: preying on SIVA for survival in the stomach. Sáenz JB, Mills JC. Journal of Clin Investigation 2020; 130(5):2183-2185.

Joint single cell DNA-seq and RNA-seq of gastric cancer cell lines reveals rules of in vitro evolution. Andor N, Lau BT, Catalanotti C, et al. NAR Genom Bioinform 2020; 2(2): lqaa016.

Aim2-mediated/IFN-β-independent Regulation of Gastric Metaplastic Lesions via CD8+ T Cells. El Zaatari et al. JCI Insight 2020; 5 (5).

Single cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment. Sathe A, Grimes SM, Lau BT, Chen J, Suarez C, Huang RJ, et al. Clin Cancer Res 2020.

A Space–Time Continuum for Immunotherapy Biomarkers in Gastroesophageal Cancer? Samuel J. Klempner, Vivek Upadhyay, Joseph Chao. Clin Cancer Res (2020) 26 (24): 6401–6403.

A functional CRISPR/Cas9 screen identifies kinases that modulate FGFR inhibitor response in gastric cancer. Chen, J., Bell, J., Lau, B.T. et al. Oncogenesis 2019; 8, 33.

Single-cell transcriptome analysis identifies distinct cell types and niche signaling in a primary gastric organoid model. Chen J, Lau BT, Andor N, Grimes SM, Handy C, Wood-Bouwens C, Ji HP. Sci Rep. 2019; 9(1):4536.

Tropism for Spasmolytic Polypeptide-Expressing Metaplasia Allows Helicobacter pylori to Expand Its Intragastric Niche. Saenz et al. Gastroenterology 2019; 156(1): 160-174.

Acid and the basis for cellular plasticity and programming in gastric repair and cancer. Saenz and Mills. Nature Reviews Gastroenterology and Hepatology 2018; 15(5): 257-273.

Indoleamine 2,3-Dioxygenase 1, Increased in Human Gastric Pre-Neoplasia, Promotes Inflammation and Metaplasia in Mice and is Associated With Type II Hypersensitivity/Autoimmunity. El-Zaatari et al. Gastroenterology 2018; 154: 140-153.

Role of Dietary Metabolites in Regulating the Host Immune Response in Gastrointestinal Disease. Mohamad El-Zaatari, John Y. Kao. Frontiers in Immunology 2017; 8:51.

Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. Greer et al. Genome Medicine 2017; 201, 9:57.

Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer drive in diffuse gastric cancer. Nadauld et al. Genome Biology 2014; 15:428.

Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Tumors with Droplet Digital PCR. Nadauld et al. Translational Medicine (Sunnyvale) 2012; 2:2, 1000107.

ACCELERATING RESEARCH TOWARD A CURE$3.8 million granted to expand research studies across the U.S.